Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
This study is ongoing, but not recruiting participants.
Study NCT00002847 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Cancer
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Kidney Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
aldesleukin
recombinant interferon alfa
conventional surgery
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Type I, Recombinant
Interferon-alpha
Interferons
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Blumenthal Cancer Center at Carolinas Medical Center
Back to top of Main Content
